Navigation Links
Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
Date:2/17/2009

proposals submitted by Reinhard Drner and Margit Zacharias.

Reinhard Drner, aged 47, a professor at the department of physics at the University of Frankfurt am Main, plans to study the special properties of tiny molecules consisting of just two or three atoms of helium experimentally. These systems have unique quantum properties that are of very great importance to basic research. For instance, the two atoms in a helium dimer are very weakly bonded and have an interatomic spacing of about 100 atomic radii making the helium dimer the largest known molecule that exists. It has been proposed that helium trimers, which consist of three helium atoms, have an entirely new, weakly bonded excited state, a so-called "Efimov state", which is currently a topic of debate. Drner's experiments will, for the first time, attempt to prove the existence of helium molecules in this state. Reinhard Drner studied physics and philosophy at the University of Frankfurt and at the RWTH Aachen. After a number of research visits to the USA, Japan and China he first took up a position as a temporary lecturer in 1998, before being appointed to the chair he now holds at the University of Frankfurt in 2002. He played a major role in the development of the reaction microscope, which has been used to achieve many important breakthroughs in the field of atomic collision physics in recent years.

Margit Zacharias, aged 52, a professor of nanotechnology at the Institute of Microsystem Technology at the University of Freiburg, is the first female recipient of Reinhart Koselleck Project funding. With her project she aims to develop new and innovative methods for doping nanostructures and, in particular, nanowires. She is thus addressing a key topic that is of immense scientific interest and, at the same time, has great potential for application in the nanoelectronics of the future. To date there is still no consistent method for defining the electronic properties of nanostructures by c
'/>"/>

Contact: Marco Finetti
marco.finetti@dfg.de
49-228-885-2230
Deutsche Forschungsgemeinschaft
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Genmab Announces Encouraging Preclinical Data for ofatumumab
4. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
5. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
6. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
7. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
8. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
9. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
10. Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
11. U-M research: New plastic is strong as steel, transparent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 Ryan Carfley , Managing ... to sit down with Bryan Hamilton, the publisher of the ... discuss talent in the Research Triangle region of North Carolina. ... highlighted at the roundtable include the role of social ... of work/life balance and the unique role that Millennials play ...
(Date:10/27/2014)... -- The Italian company Roadrunnerfoot has ... its artificial "lower limb", after the German giant ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... judgement has arrived: Roadrunnerfoot, the small Italian company ... prostheses with composite materials, has won against global ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information says ... Ebola concern in the United States ... The healthcare market researcher said the FDA,s Emergency Use Authorization ... diagnostic tests for the detection of the Ebola virus ... useful.  Kalorama routinely assess the IVD industry and its ...
(Date:10/27/2014)... MA (PRWEB) October 27, 2014 ... profit. SoundConnect , an industry leading unified ... its partners and agents to deliver cloud-based audio ... accelerate growth opportunities. , With SoundConnect’s Q4 ... every twenty-five video and/or web conferencing licenses sold, ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3SoundConnect Unveils Q4 Partner Incentives 2
... as an acceptable primary endpoint, for ... April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... reached an agreement with the U.S. Food and Drug ... 3 registration trial of OGX-011, its lead product candidate ...
... containing microneedles has proven just as effective at ... immunization. A team of researchers at Emory University ... new microneedle skin patch method of delivering flu ... people because of decreased pain, increased convenience, lower ...
... of $264.5 million grows 7.8% year-over-year- Operating margin ... Net quarterly book-to-bill ratio equates to 1.25BOSTON, April ... PRXL ) today announced its financial results for ... three months ended March 31, 2009, PAREXEL,s consolidated ...
Cached Biology Technology:OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6Flu vaccine given in microneedle skin patches proves effective in mice 2Flu vaccine given in microneedle skin patches proves effective in mice 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 2PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 5PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 6PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 7PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 8PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 9PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 10PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 11PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 12PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 13PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 14PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 15
(Date:10/29/2014)... in New York City on September 19, 2014, leading ... Society Professor of Genome Sciences and Medicine at the ... of Philosophy of Tel Aviv University, was awarded the ... In addition to her honorary degree from TAU, Prof. ... School of Medicine, and for the past 18 years ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... Cancer Genomics of the Kidney consortium ( CAGEKID ... and exposure to aristolochic acid, an ingredient in ... Nature Communications , have important implications for public ... people every year, and in Central Europe incidence ... the International Cancer Genome Consortium (ICGC), has been ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... Jewish Medical and Research Center report in the March ... proteins, known as fibulins 3 and 5, slow the ... vessels from sprouting. The proteins are promising candidates for ... fibulin proteins, which regulate cell proliferation, migration and invasion. ...
... A new UCLA imaging study shows that age-related breakdown ... wiring, correlates strongly with the presence of a key ... are detailed in the January edition of the peer-reviewed ... growing body of evidence that myelin breakdown is a ...
... in the home, but the presence of gas stresses out ... from the University of Nottingham have found that changes in ... warning of leaks in natural gas pipelines. "Our study ... monitor gas leaks via the spectrum of reflected light from ...
Cached Biology News:Proteins stop blood-vessel and tumor growth in mice 2Imaging study links key genetic risk for Alzheimer's disease to myelin breakdown 2Plants used to detect gas leaks, from outer space! 2